IMMULOGIC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Collins who wrote (42)	9/16/1996 2:47:00 PM
From: Xingbo Wang	of 305

New Phase III study From BioCentury, Sept. 16, page B10 Punk, Ziegel & Knoll analyst Shekhar Basu said IMUL has redesigned its new phase III study of Allervax for ragweed allergy based on data from a subgroup analysis of its earlier trial. The analysis showed that more severe allergy patients responded better than those who are mildly affected, and the placebo response was significantly diminished, he said. Based on those findings, the new study, which is fully enrolled with 500 patients, excluded those with mild allergy. Basu thus expects the new trial to show higher efficacy than the 11 percent response rate in the previous study, with a filing for marketing approval by mid-1997.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next